Who Paid My Doc
Jong Kim
Cumberland, MD Medical Doctor
NPI 1255334900 CMS profile 1291098
952 Seton Dr, Cumberland, MD 21502
General payments
$810
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Jong Kim of Cumberland, MD is reported in the CMS Open Payments database as having received $810 across 9 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $737 | 6 | |
| 2023 | General | $15 | 1 | |
| 2021 | General | $22 | 1 | |
| 2019 | General | $36 | 1 |
Beside peers
- Jong Kim
- Maryland median
- Middle half of Maryland
- National median
In program year 2025, general payments to Jong Kim were reported at $737. Among 20,588 Maryland profiles paid that year, the median was $166 and the middle half received between $51 and $580.
Show as a table
| Year | Jong Kim | Maryland median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $36 | $165 | $50–$633 | $163 |
| 2020 | $0 | $114 | $37–$407 | $114 |
| 2021 | $22 | $130 | $36–$480 | $132 |
| 2022 | $0 | $150 | $45–$529 | $149 |
| 2023 | $15 | $155 | $47–$557 | $160 |
| 2024 | $0 | $169 | $53–$600 | $164 |
| 2025 | $737 | $166 | $51–$580 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 242 billing codesPaid by Medicare
$579,765
Medicare patients
4,383
Services billed
27,468
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 59% | |
| Diabetes | 33% | |
| Ischemic heart disease | 24% | |
| Chronic kidney disease | 24% | |
| Depression | 21% | |
| COPD | 19% | |
| Heart failure | 16% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml A9579 | Office | 191 | 2,985 | $3,528 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 | Office | 234 | 13,905 | $1,156 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
9 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.